The pharma world's champion patent wall builder is called out for their 'drip-feed' strategy to safeguard the next megablockbuster franchise
By all accounts, AbbVie holds the title as a master builder of patent walls. Its work on Humira has been both legendary and extraordinarily controversial, encircling a cash cow that can be milked without any generic rivals butting in until 2023 — as new and better drugs come along to outperform the copycats to come.
And now a group of patient advocates at I-MAK say AbbVie is deep into building its second high security patent perimeter around Imbruvica — the next Humira in the AbbVie portfolio.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.